CBIO - Catalyst Biosciences, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.7600
-0.1900 (-4.81%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.9500
Open3.9200
Bid3.6000 x 800
Ask3.7700 x 900
Day's Range3.6200 - 3.9295
52 Week Range3.4300 - 10.7800
Volume185,694
Avg. Volume280,623
Market Cap65.366M
Beta (5Y Monthly)2.25
PE Ratio (TTM)N/A
EPS (TTM)-4.5960
Earnings DateFeb 19, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateAug 19, 2015
1y Target Est21.00
  • How Much is Catalyst Biosciences, Inc.'s (NASDAQ:CBIO) CEO Getting Paid?
    Simply Wall St.

    How Much is Catalyst Biosciences, Inc.'s (NASDAQ:CBIO) CEO Getting Paid?

    Nassim Usman became the CEO of Catalyst Biosciences, Inc. (NASDAQ:CBIO) in 2015. This analysis aims first to contrast...

  • Catalyst Biosciences Enters Oversold Territory
    Zacks

    Catalyst Biosciences Enters Oversold Territory

    Catalyst Biosciences has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

  • GlobeNewswire

    Catalyst Biosciences to Present at the Cowen Healthcare Conference

    Catalyst Biosciences, Inc. (CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer of Catalyst Biosciences, will present a corporate overview at the Cowen Healthcare Conference at 8:40 a.m. ET on Tuesday, March 3, 2020, in Boston. Catalyst is a clinical-stage biopharmaceutical company focused on addressing unmet needs in rare diseases and systemic complement mediated disorders.

  • GlobeNewswire

    Catalyst Biosciences Reports Fourth Quarter and Full-Year 2019 Operating & Financial Results and Provides a Corporate Update

    Presented positive clinical and pre-clinical data from its MarzAA and DalcA hemophilia programs Announced a global license and collaboration agreement with Biogen to develop.

  • GlobeNewswire

    Catalyst Biosciences Announces Closing of Public Offering of Common Stock

    Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and other rare bleeding disorders, (the Company), today announced the closing of an underwritten public offering of 5,307,692 shares of its common stock, offered at a price of $6.50 per share to the public, which includes the exercise in full by the underwriters of their 30-day option to purchase up to an additional 692,307 shares of its common stock. The gross proceeds to the Company from this offering were approximately $34.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company.

  • GlobeNewswire

    Catalyst Biosciences Announces Pricing of Public Offering of Common Stock

    Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and other rare bleeding disorders,  (the Company), today announced the pricing of an underwritten public offering of 4,615,385 shares of its common stock, offered at a price of $6.50 per share to the public. Additionally, the Company has granted the underwriters a 30-day option to purchase up to an additional 692,307 shares of its common stock. All of the shares in the offering are being offered by the Company.

  • GlobeNewswire

    Catalyst Biosciences Announces Proposed Public Offering of Common Stock

    Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and other rare bleeding disorders (the Company), today announced that it is offering shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, the Company expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the public offering.

  • Benzinga

    The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 6) Acceleron Pharma Inc (NASDAQ: XLRN ) Alector Inc (NASDAQ: ...

  • GlobeNewswire

    Catalyst Biosciences Presents Positive Data from its Phase 2b Trial of Subcutaneous Dalcinonacog Alfa (DalcA) and Marzeptacog alfa (activated) (MarzAA) Programs at the 13th Annual EAHAD Congress

    Catalyst Biosciences, Inc. (CBIO), today announced positive efficacy and safety data from its Phase 2b trial of DalcA, a next-generation subcutaneously (SQ) administered Factor IX (FIX) therapy being developed for the treatment of hemophilia B. The data were presented by Johnny Mahlangu, M.B.B.Ch., M.Med, F.C.Path, professor of haematology, faculty of health sciences, head of the School of Pathology at the University of Witwatersrand in Johannesburg, South Africa, and principal investigator in the clinical trial in an oral presentation at the 13th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) in The Hague, Netherlands. Data from the trial showed that 28 days of daily SQ dosing of DalcA achieved protective target FIX levels of 12%, with steady state FIX levels of up to 27% after 14 days with no bleeds, demonstrating effective prophylaxis and the potential for lower or less frequent dosing.

  • GlobeNewswire

    Catalyst Biosciences Announces Oral and Poster Presentations at the 13th Annual EAHAD Congress

    SOUTH SAN FRANCISCO, Calif., Jan. 27, 2020 -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced one oral and three poster presentations at the 13th Annual Congress of.

  • GlobeNewswire

    Catalyst Biosciences Announces Addition of Geoffrey Shiu Fei Ling, M.D. and Sharon Tetlow to Board of Directors

    Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and other rare bleeding disorders, today announced the appointment of Geoffrey Shiu Fei Ling, M.D. and Sharon Tetlow to the Company’s Board of Directors, effective January 15, 2020. Ms. Tetlow is Managing Partner and Founder of Potrero Hill Advisors. Throughout her career as a serial Chief Financial Officer, Ms. Tetlow has held board seats, served on Audit and Transaction Committees through successful acquisitions, served as the board’s financial expert and has been the CFO of public companies.

  • Imagine Owning Catalyst Biosciences (NASDAQ:CBIO) And Wondering If The 31% Share Price Slide Is Justified
    Simply Wall St.

    Imagine Owning Catalyst Biosciences (NASDAQ:CBIO) And Wondering If The 31% Share Price Slide Is Justified

    It is a pleasure to report that the Catalyst Biosciences, Inc. (NASDAQ:CBIO) is up 38% in the last quarter. But that...

  • Company News For Dec 20, 2019
    Zacks

    Company News For Dec 20, 2019

    Companies In The News Are: CAG, CBIO, MLHR, DRI

  • Catalyst Biosciences Inc (CBIO): Hedge Fund Sentiment Unchanged But Bullish
    Insider Monkey

    Catalyst Biosciences Inc (CBIO): Hedge Fund Sentiment Unchanged But Bullish

    Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed in recent years. However, hedge funds are generally partially hedged and aim at […]

  • Benzinga Pro's Top 5 Stocks To Watch For Thurs., Dec. 19, 2019: NKE, TIVO, CBIO, APOG, RAD
    Benzinga

    Benzinga Pro's Top 5 Stocks To Watch For Thurs., Dec. 19, 2019: NKE, TIVO, CBIO, APOG, RAD

    Benzinga Pro's Stocks To Watch For Thursday NIKE (NKE) - Shares were up 0.4% premarket ahead of earnings from the company after hours Thursday. Analysts expect NIKE to report around $0.58 in quarterly ...

  • GlobeNewswire

    Catalyst Biosciences Announces Global License and Collaboration Agreement to Develop Pegylated CB 2782 for the Treatment of Dry Age-Related Macular Degeneration

    Catalyst Biosciences, Inc. (CBIO), today announced it has entered into a global license and collaboration agreement with Biogen Inc. (BIIB) for the development and commercialization of pegylated CB 2782 (CB 2782-PEG) for the potential treatment of geographic atrophy (GA) associated dry age-related macular degeneration (dry AMD). Under the terms of the agreement, Biogen will receive an exclusive worldwide license to develop and commercialize CB 2782-PEG and Catalyst’s other anti-C3 proteases for the potential treatment of dry  AMD. Catalyst will perform pre-clinical and manufacturing activities and Biogen will be solely responsible for funding the pre-clinical and manufacturing activities and performing Investigational New Drug (IND)-enabling activities, worldwide clinical development, and commercialization.

  • GlobeNewswire

    Catalyst Biosciences Presents Two Posters on MarzAA at the 61st Annual American Society of Hematology Conference

    Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and other rare bleeding disorders, today announced two poster presentations on Marzeptacog alfa (activated) – MarzAA, the Company’s subcutaneously administered next-generation engineered coagulation Factor VIIa (FVIIa), at the 61st Annual American Society of Hematology (ASH) meeting held December 7-10, 2019 in Orlando, Florida. In the first poster, entitled: Fast Onset of Action of Subcutaneously Administered Marzeptacog Alfa (Activated) Supports On-Demand Treatment in Hemophilia A Mice, Dr. Grant Blouse, PhD, vice president of translational research at Catalyst Biosciences presented data demonstrating MarzAA’s potential as an on-demand therapy to treat acute ongoing bleeding in hemophilia.

  • GlobeNewswire

    Catalyst Biosciences to Present at the Stifel Healthcare Conference

    Catalyst Biosciences, Inc. (CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer of Catalyst Biosciences, will present a corporate overview at the Stifel 2019 Healthcare Conference at 9:10 a.m. ET on Tuesday, November 19, 2019, in New York.

  • GlobeNewswire

    Catalyst Biosciences Reports Third Quarter 2019 Operating & Financial Results and Provides a Corporate Update

    SOUTH SAN FRANCISCO, Calif., Nov. 07, 2019 -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the third quarter ended.

  • GlobeNewswire

    Catalyst Biosciences Announces Poster Presentations at the 61st Annual American Society of Hematology Conference

    SOUTH SAN FRANCISCO, Calif., Nov. 06, 2019 -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company developing novel medicines to address.

  • We're Keeping An Eye On Catalyst Biosciences's (NASDAQ:CBIO) Cash Burn Rate
    Simply Wall St.

    We're Keeping An Eye On Catalyst Biosciences's (NASDAQ:CBIO) Cash Burn Rate

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

  • Company News For Oct 4, 2019
    Zacks

    Company News For Oct 4, 2019

    Companies in the news are: STZ, BBBY, PEP, CBIO

  • GlobeNewswire

    Catalyst Biosciences Provides DalcA Phase 2b Trial Update

    Catalyst Biosciences, Inc. (CBIO), today provided an update on enrollment in its Phase 2b study of dalcinonacog alfa (DalcA), a next-generation subcutaneously (SQ) administered Factor IX (FIX) therapy being developed for the treatment of hemophilia B. Two subjects have completed dosing and washout, Factor IX levels in these two subjects exceeded the trial efficacy endpoint of 12% activity and no anti-drug antibodies were detected. Enrollment is ongoing and the Company anticipates reporting final data in the first half of 2020. “We believe that DalcA may offer a conveniently-dosed subcutaneous prophylactic treatment option that could significantly improve the quality of life for those suffering from severe hemophilia B,” said Nassim Usman, Ph.D., president and chief executive officer of Catalyst.

  • 22NW: Catalyst Biosciences Needs Change Now
    PR Newswire

    22NW: Catalyst Biosciences Needs Change Now

    SEATTLE , Oct. 2, 2019 /PRNewswire/ -- Dear Catalyst Biosciences, Inc. Shareholders: 22NW, LP ("22NW" or "we") is one of the largest shareholders of Catalyst Biosciences, Inc (the "Company") ...